FDA will survey how visuals distract viewers

Share this article:
The FDA will test broadcast-style ads for a bogus blood pressure drug as part of a survey aimed at determining how visuals may distract viewers from risk information. The survey of 2,400 consumers—ages 40 and up—will feature several executions of the bogus ads to evaluate recall and comprehension of risk information. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters